Mir Imran founded InCube Laboratories in 1995 to focus on his passion: creating medical device solutions that change the standard of care in critical healthcare markets. Mir began his career as a med-tech entrepreneur in the late 1970’s, and has founded numerous game-changing companies since those early days. Over the decades, he has become one of the world’s most successful inventors, entrepreneurs and investors in healthcare.
Mir now holds more than 200 issued patents – and is perhaps most well known for his pioneering contributions to the first FDA-approved Automatic Implantable Cardioverter Defibrillator. However Mir has invented a number of breakthrough devices that set new standards of care for their industries. Highlights include depth of anesthesia monitors, Trans-Urethral Needle Ablation (TUNA) procedures, embolic protection devices, and systems to treat cardiac tachyarrhythmias. Mir's current crop of inventions includes advanced treatments for neural aneurysms, epilepsy, ulcerative colitis, obesity and chronic pain, among others. Most of these will enter clinical trials in the 2008 to 2010 timeframe.
As an entrepreneur, Mir has founded over 20 medical device companies, including: Vidamed (acquired by Medtronic), Physiometrix (IPO 1996), Cardiac Pathways (IPO 1996), Advanced Cytomextrix (acquired by Oncotech 1997), Percusurge (acquired by Medtronic 2001), Reflow, Inc. (acquired 1999), Safeview (acquired by L3 2006) Intrapace ( founded 2001), Spinal Modulation (founded 2005) and Zonare (founded 1999).
As an investor, Mir serves as the Life Science Venture Partner for DFJ ePlanet, where he has led 9 investments in a range of promising ventures around the globe. In addition to his venture capital activities, Mir is an active angel investor, with a portfolio based around both medical and pharmaceutical ventures. Mir currently holds board seats with Bodymedia, Cardiovasc, Intrapace, Egeen International, Spinal Modulation, ZARS and Zonare.
Mir holds an MS in Bio-Engineering and a BS in Electrical Engineering from Rutgers, where he spent three years as a Research Specialist.
